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Human HDL-associated paraoxonase (PON1) hydrolyzes a number of toxic organophosphorous compounds and
reduces oxidation of LDLs and HDLs. These properties of PON1 account for its ability to protect against pesticide
poisonings and atherosclerosis. PON1 also hydrolyzes a number of lactone and cyclic-carbonate drugs. Among
individuals in a population, PON1 levels vary widely. We previously identified three polymorphisms in the PON1
regulatory region that affect expression levels in cultured human hepatocytes. In this study, we determined the
genotypes of three regulatory-region polymorphisms for 376 white individuals and examined their effect on plasma-
PON1 levels, determined by rates of phenylacetate hydrolysis. The 5108 polymorphism had a significant effect
on PON1-activity level, whereas the 5162 polymorphism had a lesser effect. The 5909 polymorphism, which is
in linkage disequilibrium with the other sites, appears to have little or no independent effect on PON1-activity
level in vivo. Other studies have found that the L55M polymorphism in the PON1-coding region is associated with
differences in both PON1-mRNA and PON1-activity levels. The results presented here indicate that the L55M
effect of lowered activity is not due to the amino acid change but is, rather, largely due to linkage disequilibrium
with the5108 regulatory-region polymorphism. The codon 55 polymorphism marginally appeared to account for
15.3% of the variance in PON1 activity, but this dropped to 5% after adjustments for the effects of the 5108
and Q192R polymorphisms were made. The 5108C/T polymorphism accounted for 22.8% of the observed
variability in PON1-expression levels, which was much greater than that attributable to the other PON1 poly-
morphisms. We also identified four sequence differences in the 3′ UTR of the PON1 mRNA.
Introduction
Human paraoxonase (PON1 [MIM 168820]) is an
HDL-associated enzyme (Kitchen et al. 1973; Don et al.
1975; Mackness et al. 1985). PON1 was first investi-
gated for its ability to hydrolyze organophosphorous
(OP) compounds, such as the highly toxic oxon forms
of the pesticides parathion (Aldridge 1953; Playfer et al.
1976; Geldmacher-v Mallinckrodt et al. 1979), chlor-
pyrifos (Furlong et al. 1988, 1989), and diazinon, as
well as the nerve agents sarin and soman (Davies et al.
1996). In recent years, PON1 has been found to protect
LDL and HDL from oxidation (Watson et al. 1995;
Aviram et al. 1998a, 1998b;Mackness et al. 1998b;Cao
et al. 1999). The classes of substrates for PON1 that
most recently have been identified include a number of
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drugs and a drug precursor, with important pharma-
cokinetic implications. Tongou et al. (1998) have shown
that the prodrug NM441 is converted to its active form
(NM394) by PON1, and Billecke et al. (2000) have
shown that PON1 metabolizes lactones and cyclic-car-
bonate esters, including several of the statin drugs used
to control cholesterol levels. The hydrolysis of gluco-
corticoid g-lactones and cyclic-carbonate esters by
PON1 provides a mechanism to confine the active forms
of drugs to their target sites (e.g., lung) by rapidly me-
tabolizing them as they enter the plasma (Biggadike et
al. 2000).
Several types of evidence suggest that low levels of
PON1 protein raise the risk and severity of both OP
poisoning and atherosclerosis. Species with low PON1
activity are more sensitive to OP poisoning than are
species with higher PON1 activity (Costa et al. 1987).
PON1-null mice on a high-fat diet had larger athero-
sclerotic lesions than were seen in either wild-type or
heterozygous mice (Shih et al. 1998). Additionally,
PON1-null mice are 5–10 times more sensitive to cho-
linesterase inhibition by diazoxon and chlorpyrifos
oxon than are wild-type mice (Furlong et al. 1998; Shih
et al. 1998; Li et al. 2000); however, intraperitoneal
injection of purified PON1 into these mice reconstitutes
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Table 1
Allele Frequencies of the PON1 Polymorphisms
POSITION
AND ALLELE
FREQUENCY REPORTED BY
Present
Study
Leviev
and
James
(2000)
Suehiro
et al.
(2000)
James et al.
(2000b)
CHD CHD
909:
G .46 .41 … … …
C .54 .59 … … …
162:
A .23 … .10 … …
G .77 … .90 … …
108:
C .50 .46 .48 .44 .51
T .50 .54 .52 .56 .49
55:
L .64 .65 .94 .62 .60
M .36 .35 .06 .38 .40
192:
Q .73 .69 .40 .67 .73
R .27 .31 .60 .33 .27
Table 2
x2 P Values for Pairs of PON1 Polymorphisms
Demonstrating Linkage Disequilibrium
POSITION
P AT
909 162 108 55 192
909 … !.001 !.001 !.001 .004
162 … !.001 !.001 .017
108 … !.001 .002
55 … !.001
192 …
plasma PON1 and resistance to diazoxon and chlor-
pyrifos oxon (Li et al. 2000). In humans, wide variation
(i.e., 13-fold) in PON1-protein levels has been found
among individuals (La Du et al. 1986; Furlong et al.
1989; Davies et al. 1996; Richter and Furlong 1999).
Relative to that in controls, PON1 activity has been
found to be lower in individuals with either non–insulin-
dependent diabetes mellitus (Mackness et al. 1998c; Sa-
kai et al. 1998), familial hypercholesterolemia (Tomas
et al. 2000), coronary artery disease (James et al.
2000b), or carotid artery disease (Jarvik et al. 2000).
The PON1-coding region contains two common
polymorphisms, a leucine (L) to methionine (M) sub-
stitution at codon 55 and a glutamine (Q) to arginine
(R) substitution at codon 192 (Adkins et al. 1993; Hum-
bert et al. 1993). The Q192R polymorphism causes sub-
strate-dependent differences in the kinetics of hydrolysis
by each PON1192 isoform, such that paraoxon (Adkins
et al. 1993; Humbert et al. 1993; Li et al. 2000) and
chlorpyrifos oxon (Li et al. 2000) are hydrolyzed in
vitro more efficiently by PON1R192, whereas soman and
sarin are hydrolyzed more rapidly by PON1Q192 (Davies
et al. 1996). The Q192R polymorphism has been re-
ported to affect the enzyme’s in vivo ability to hydrolyze
oxidized lipids, in both LDL and HDL (Aviram et al.
1998a; Mackness et al. 1998b; Cao et al. 1999). The
PON155 polymorphism does not affect the catalytic ef-
ficiency of substrate hydrolysis by the enzyme, but the
PON1M55 allele is correlated with decreased mRNA and
protein levels (Blatter Garin et al. 1997; Leviev et al.
1997; Mackness et al. 1998c; Brophy et al. 2000).
Although the substrate-dependent PON1 Q192R
polymorphism has been examined in some detail, the
genetic basis for the high interindividual variability in
serum PON1 levels has just recently begun to be un-
derstood. Our laboratory and two other groups recently
identified five polymorphisms in the PON1 regulatory
region (Leviev and James 2000; Suehiro et al. 2000;
Brophy et al. 2001); these polymorphisms are at 107/
108, 126, 160/162, 824/832, and 907/
909, where the base immediately preceding the start
codon is numbered as “1.” The nomenclature differ-
ences for four of the polymorphisms are likely due to
small variations in the sequences examined by the three
different groups. In our laboratory, data generated from
cell-culture experiments with a reporter gene indicated
that three of the five polymorphisms had a functional
effect on PON1 expression (Brophy et al. 2001). In this
report, we examine the three PON1 regulatory-region
polymorphisms—that is, 108, 162, and 909—to
determine their effects on PON1 activity level in a white
population sample.
Material and Methods
Samples
Genomic DNA and lithium-heparin–plasma samples
were obtained from volunteers who were participants in
a project at the Puget Sound Veterans Affairs Health
Care System (PSVAHCS) Epidemiology Research and
Information Center. The white sample population con-
sisted of control subjects and patients (97.0%male) with
varying degrees of carotid artery disease. Individuals
with internal stenosis !15% (controls), 15%–80%, or
180% comprised 49.1%, 10.5%, and 40.4% of the pop-
ulation, respectively. No differences in PON1192 gene
frequencies between the patients and the controls were
observed in this group; details of subject selection can
be found in the report by Jarvik et al. (2000). Subject
DNA was prepared from buffy-coat preparations, by a
modification of the procedure of Miller et al. (1988),
with Puregene reagents (Gentra). The study was ap-
proved by both the University of Washington and the
PSVAHCS human-subject review processes. All subjects
gave written, informed consent.
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Table 3
Mean SD Arylesterase Activity, for
Each PON1 Genotype
Position and
Genotype
(No. of Cases)
Mean SD
Arylesterase
Activity
(U/ml) Pa
909: !.001
GG (79) 128.8  46.0
CG (189) 103.0  37.5
CC (108) 73.9  32.9
162: !.001
AA (18) 135.9  50.4
AG (140) 117.1  41.4
GG (218) 86.2  37.2
108: !.001
CC (94) 125.8  45.6
CT (188) 102.9  37.6
TT (94) 68.6  27.9
55: !.001
LL (147) 115.0  42.8
LM (185) 94.0  39.7
MM (44) 75.9  38.3
192: .015
QQ (195) 104.1  45.4
QR (158) 98.5  40.3
RR (23) 77.4  27.4
a Evaluated by ANOVA.
Figure 1 Arylesterase activity in individuals homozygous for
both polymorphisms associated with either high or low plasma-PON1
activity. For 108CC/162AA, and meanp 140.9 U/ml; forNp 14
108TT/162GG, , meanp 67.5 U/ml, and (t-test).Np 89 P ! .001
(Data available on request from the corresponding author.)
Genotyping
All genotyping was conducted by PCR amplification,
followed by polymorphism-specific restriction diges-
tion and gel electrophoresis. The Q192R polymor-
phism was detected by AlwI digestion, and the L55M
polymorphism was detected by NlaIII digestion, as de-
scribed elsewhere (Humbert et al. 1993). The genotype
of the 108 polymorphism was determined by PCR
amplification with primers GACCGCAAGCCACGCC-
TTCTGTGCACC and TATATTTAATTGCAGCCGCA-
GCCCTGCTGGGGCAGCGCCGATTGGCCCG-
CCGC, with 5% dimethyl sulfoxide (DMSO) and Taq
polymerase (Promega) and at an annealing temperature
of 63C, for 25 cycles. The latter primer creates a BstUI
site (New England Biolabs) when a C is present at
108. After digestion, the products were analyzed by
3% agarose gel (Sigma). Presence of a 108C allele
results in digested bands of 52 bp and 67 bp (instead
of an undigested band of 119 bp). The 162A/G poly-
morphism was PCR amplified with primers GCTATT-
CTTCAGCAGAGGGT and TGAATCTGTAGCCAG-
GGCAC, with 5% DMSO and Taq polymerase and at
an annealing temperature of 56C, for 30 cycles. The
1,210-bp PCR product was digested with BstUI and
was electrophoresed through 1% agarose. Digested
bands (674 bp and 536 bp) indicated the presence of
G at 162, whereas absence of digestion indicated the
presence of an A allele. The 909G/C polymorphism
was PCR amplified with primers AACATGTCACTGT-
GGCATATATAATGCTC and TATTATAATATATT-
ATATCATTCACAGTAACAGCAGACAGCAGAGA-
AAAGA, with 5% DMSO and Taq polymerase and at
an annealing temperature of 60C, for 35 cycles. The
latter primer removes a second BsmAI site, leaving one
BsmAI site when a G is present at 909, resulting in
digested bands of 50 bp and 206 bp.
PON1-Activity Assays
Rates of phenylacetate hydrolysis (arylesterase activ-
ity) are neutral with respect to theQ192Rpolymorphism
and are in a linear relationship with PON1-expression
levels (Furlong et al. 1993; Blatter Garin et al. 1997).
Arylesterase activities for individuals with sequence dif-
ferences in the 3′ UTR were determined as described
elsewhere (Kitchen et al. 1973). Arylesterase activities of
the population whose regulatory-region polymorphisms
were studied were determined as above, except that a
SpectraMax Plus (Molecular Devices) plate reader was
used to measure rates of hydrolysis. Ten microliters of
a 1:40 dilution of human plasma was mixed with 200
ml of substrate (3.26 mM phenylacetate in 9 mM Tris-
Cl pH 8 and 0.9 mM CaCl2). The rates of hydrolysis
were determined by analysis in a plastic UV-transparent
96-well plate (Costar), at 270 nm for 4 min. The initial,
linear rates of hydrolysis were used for rate calculation.
Samples were assayed in triplicate. Because of the dif-
ference in assay format, a conversion factor was nec-
essary for comparison of the data versus the results of
the standard assay, in a 1-cm quartz cuvette. A subset
of samples was assayed by both methods, and the aryl-
esterase activity (in U/ml) was calculated; the results
were plotted against each other, and a linear-regression
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Table 4
Mean SD Arylesterase Activity, for PON1 Regulatory-Region
Genotypes
Position 909 162 108
No. of
Cases
Mean SD
Arylesterase
Activity
(U/ml) P
909 CC GG CT 20 96.0  41.5 .959
CG GG CT 83 96.5  35.8
162 CG AG CT 80 109.3  36.9 .026
CG GG CT 83 96.5  35.8
108 CC GG CT 20 96.0  41.5 .009
CC GG TT 86 68.2  28.1
All three GG AA CC 14 140.9  52.7 !.001
CG AG CT 80 109.3  36.9
CC GG TT 86 68.2  28.1
line was drawn ( ). To convert the plate-reader2R p .93
results for comparison with standard DU70 spectropho-
tometer-determined rates, the intercept (18,950 U/ml)
was subtracted from the plate-reader assay arylesterase
activity, and the result was divided by the slope (2,105.8
U/ml).
Identification of 3′ UTR Sequence Differences
The regions encompassing the poly(A) signal se-
quences were PCR amplified from genomic DNA prepa-
rations from four individuals: one with low plasma
PON1 arylesterase activity, one with intermediate
plasma PON1 arylesterase activity, and two with high
plasma PON1 arylesterase activity. The PCR primers
used were GGACATCATGAAGCATCAAAGC and
CCTATGTGTCATTGCAACAGG. The PCR products
were cloned into plasmid pCRII and then were se-
quenced by AmpliTaq FS dye terminator cycle sequenc-
ing (Perkin-Elmer) and primer M13 (forward).
Statistical Analyses
Statistical analysis was conducted with SPSS 8.0 (SPSS).
The x2 test was used both to test if genotype frequencies
deviated from Hardy-Weinberg–equilibrium expectations
and to evaluate the significance of the linkage disequilib-
rium between each polymorphism pair. Arylesterase-ac-
tivity differences between genotypes were evaluated by
either analysis of variance (ANOVA) or t-test, and, of the
total variance (vt) in arylesterase activity, the proportion
(vg/vt) due to each of the five genetic polymorphisms was
estimated two ways: first, the marginal effect that each
polymorphism had on unadjusted arylesterase activity
was estimated as the genetic variance divided by the total
variance; second, the conditional effect of each polymor-
phism, given the effect of polymorphisms with a greater
effect, was sequentially estimated. The PON1108 poly-
morphism had the greatest effect; thus, linear regression
with two dummy variables was used to adjust arylesterase
for the PON1108 genotypes. The regression residuals
were relocated to the arylesterase mean of 100.0742 U/
ml, and, of the total variance of each relocated residual
genetic variance, the proportion due to each additional
polymorphism was computed. The polymoprhism with
the greatest effect was then adjusted for, and the new
residuals were tested for the effects of the remaining poly-
morphisms. This process was repeated until all polymor-
phisms had been considered.
Results
A total of three PON1 regulatory-region polymorphisms
(108C/T, 162A/G, and 909G/C) and two PON1
coding-region polymorphisms (L55M and Q192R) were
genotyped in a population of 376 white individuals. The
allele frequencies determined, shown in table 1, are con-
sistent with published reports on whites (Cascorbi et al.
1999; James et al. 2000b; Leviev and James 2000). The
allele frequencies for both the coding-region and the
162 regulatory-region polymorphisms differed from
those of a Japanese population, as expected (Imai et al.
2000; Suehiro et al. 2000), although the 108 allele
frequencies did not differ. Genotypes at all five positions
do not deviate from Hardy-Weinberg–equilibrium ex-
pectations. There is significant linkage disequilibrium
across the entire regulatory region (table 2). As described
elsewhere (Blatter Garin et al. 1997; Mackness et al.
1998c; Schmidt et al. 1998), the PON155L allele also is
in linkage disequilibrium with the PON1192R allele. In
addition, we observed that PON155L is in linkage dis-
equilibrium with 108C, 162A, and 909G.
Arylesterase activities for each genotype were eval-
uated by ANOVA to test for evidence of genotype effect
on activity level (table 3). Each polymorphism, whether
coding or noncoding, is associated with statistically sig-
nificant variability in arylesterase values. Comparison
of individuals with two (fig. 1) or three (table 4) of the
regulatory-region polymorphisms associated with high
expression versus those with the regulatory-region poly-
morphisms associated with low expression reveals a
twofold difference in activity levels.
Although each polymorphism genotyped in this study
is associated with variability in arylesterase activity, the
linkage disequilibrium among all of these polymor-
phisms makes it unclear whether activity differences
were due to a specific polymorphism or to linkage dis-
equilibrium with another position. We used two strat-
egies to reduce this confounding effect: first, we sub-
divided the subjects by genotype at each of the three
regulatory-region polymorphisms; second, we exam-
ined the residual genetic variance when adjustments
were made for sites with greater effects. Each regula-
tory-region position was examined for PON1-activity
differences while the genotype at the other two regu-
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Table 5
Estimated Marginal and Serial Conditional Proportions vg/vt of the Total Variance vt, in Arylesterase
Activity, Due to Each of the Five Genetic Polymorphisms
PON1
SITE
vg/vt
MARGINAL
ARYLESTERASE
ADJUSTED FOR vt
MEANa
vg/vt
CONDITIONAL1 2 3
108 .228 1,831.31 125.80 102.94 68.61 .228
192 .022 108 1,413.22 105.88 97.50 68.53 .057
55 .153 108, 192 1,330.32 109.09 95.40 89.60 .041
162 .095 108, 192, 55 1,250.83 112.17 102.71 97.38 .011
909 .205 108, 192, 162, 55 1,231.25 101.16 99.09 101.01 .001
a Means 1, 2, and 3 are those of the three genotypes—pp, pq, and qq—for each site, for the arylesterase
trait adjusted for the polymorphisms listed. The p allele for sites 108, 192, 55, 162, and 909,
respectively, are C, Q, L, A, and C. The overall arylesterase mean was 100.0742 U/ml.
latory-region polymorphism positions was held con-
stant (table 4). The 108 haplotype pair showed a sig-
nificantly higher PON1-activity level when C was
present compared to when T was present. Likewise, the
162A allele had a statistically significant effect, al-
though the arylesterase-activity level differences were
less than those for 108 and were not adjusted for
linkage disequilibrium with 55 or 192. When the geno-
types at 55 and 192 (LM and QQ, respectively) were
also held constant, 162 remained significant (Pp
). In contrast, the909G/C polymorphism appears.025
not to independently affect PON1-activity levels.
Estimated marginal proportions and conditional pro-
portions, vg/vt, of the total variance, vt, in arylesterase
activity that are due to each of the five genetic poly-
morphisms are given in table 5. The greatest effect ap-
pears to be that of the PON1108 site, accounting for
22.8% of the variation in arylesterase activity. The sig-
nificant linkage disequilibrium between the polymor-
phisms results in dependence between the estimated mar-
ginal vg/vt. Given the effect of the PON1108 site, 5.7%
of the remaining variance is associated with PON1192.
Given the PON1108- and PON1192-site effects, 4.1% of
the remaining variance is associated with the PON155
polymorphism. The PON1162 site accounts for only
1.1% of the variance in PON1108-, PON1192-, and
PON155-adjusted arylesterase activity. The effect of the
PON1909 polymorphism that appeared, for marginal vg/
vt, quite great (20.5 %; table 5) is trivial, once the other
polymorphisms are accounted for.
As described elsewhere (Blatter Garin et al. 1997;
Mackness et al. 1998c; Brophy et al. 2000), individuals
with PON155LL show, on average, a higher level of en-
zyme activity than do individuals with PON155MM (table
3). The difference in expression level is statistically sig-
nificant ( ) and has been suggested to be due toP ! .001
linkage to other elements, such as regulatory-region
polymorphisms (Leviev and James 2000). Our analysis
showed that the M allele is indeed in linkage disequi-
librium with the regulatory-region polymorphism (i.e.,
108T) associated with lower PON1 expression.When
the 108 genotype was held constant, arylesterase val-
ues shown were not significantly different between in-
dividuals with genotype LL and those with genotype
MM (fig. 2 and table 6).
The polymorphisms identified in the regulatory re-
gion explain part of the variation in PON1-expression
levels; however, a significant portion of that variation
is still unexplained. We examined the 3′ UTR of PON1
mRNA from four individuals, by sequence analysis. The
clones differed in the location of their poly(A) tails, and
none of the sequences contained a canonical poly(A)
signal of AATAAA; instead, sequences from the clones
revealed the use of variants of this sequence (data not
shown). Four sequence differences were identified in the
3′ UTR (table 7), but none altered the poly(A) signal
sequences. These 3′ sequence differences have not yet
been examined for their effects on expression level or
for their frequencies in the population.
Discussion
The allele frequencies for PON1 polymorphisms differ
among ethnic groups, as shown in table 1. Notably, the
only position that does not differ, in allele frequency,
between white and Japanese populations, in either the
coding or the upstream regulatory region, is108. This
may be a coincidence, or selection pressure(s) may have
acted on this polymorphism to maintain specific allele
frequencies across different ethnic groups.
The three regulatory and the two coding polymor-
phisms all show significant linkage disequilibrium to
each other, including the four alleles associated with
high expression (i.e.,108C,162A, 55L, and 192Q).
The results summarized in table 5 suggest that the
PON1108 polymorphism has the greatest effect on ar-
ylesterase activity, followed, in order, by PON1192,
PON155, PON1162, and PON1909. It is possible that
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Figure 2 Arylesterase activity in individuals with each 55/108
haplotype. Means and P values are shown in table 6. The graphs
indicate PON1 regulatory-region genotypes of108CC (A),108CT
(B), and 108TT (C). (Data available on request from the corre-
sponding author.)
Table 6
Mean SD Arylesterase Activity for Each 55/
5108 Haplotype
GENOTYPE
No. of
Cases
MEAN SD
ARYLESTERASE
ACTIVITY
(U/ml) P108 55
CC LL 67 129.9  43.2 .349
CC LM 24 116.9  50.8
CC MM 3 104.4  56.7
CT LL 63 110.3  38.6 .154
CT LM 113 99.5  36.4
CT MM 12 96.2  41.3
TT LL 17 73.2  20.4 .572
TT LM 48 69.5  28.5
TT MM 29 64.5  30.9
any of the effects listed are, at least in part, due to
linkage disequilibriumwith other, still unidentified poly-
morphisms. Our results indicate that the 909G/C
polymorphism has little, if any, effect on PON1-activity
level but is in linkage disequilibrium with the functional
polymorphisms. Interestingly, 108C and 162A, the
two regulatory-region alleles that may independently
increase PON1 expression (table 4) are in linkage dis-
equilibrium with each other. The 108C allele is also
in linkage disequilibrium with the PON1R192 allele,
which has been implicated in a lower level of protection
against atherosclerosis, although the Q192R polymor-
phism is associated with activity variance that is inde-
pendent of the108C site. It is possible that the108C
allele that increases expression may partly compensate
for the lowered protection afforded by the PON1R192
isoform, complicating the apparent relationship be-
tween the PON1192 genotype and disease. The L55M
polymorphism has been associated with PON1-expres-
sion level (Blatter Garin et al. 1997; Leviev et al. 1997;
Mackness et al. 1998c; Brophy et al. 2000). The results
presented here (fig. 2 and tables 5 and 6) indicate that
the PON155 effect is primarily due to linkage disequi-
librium of PON155M with the 108T lower-expression
variant.
The lack of effect of the 909 polymorphism con-
trasts with the increased expression from 909G ob-
served in our cell-culture experiments (Brophy et al.
2001). This discrepancy may be due to an inherent dif-
ference between a cultured hepatocarcinoma cell line
and plasma from normal individuals. Alternatively, se-
quence-context effects may alter the significance of the
909 polymorphisms; for instance, the 909G allele
may have an affect when 162A is present in cis (in
vitro data) but not when other polymorphisms are pres-
ent. We do not have plasma and genotypes from enough
individuals of these specific haplotypes to investigate
that possibility.
The108 polymorphism lies within a probable bind-
ing site for Sp1, a ubiquitous transcription factor com-
mon in TATA-less genes such as PON1. James et al.
(2000b) found that the 108T allele was associated
with increased risk of coronary artery disease in patients
with type 2 diabetes. The 162 polymorphism may be
within a possible NF-1 transcription-factor–binding site
(Brophy et al. 2001). Interestingly, a recent publication
has identified an interleukin-6 (IL-6)–responsive ele-
ment that shows homology to the sequence including
and 3′ of the 162 polymorphism (Ray 2000). IL-6, a
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Table 7
Examination Results from 3′ UTR of PON1 mRNA
INDIVIDUAL
(ALLELE AT
192)
ARYLESTERASE
ACTIVITY
(U/ml)
NO. OF
CLONES
SEQUENCE DIFFERENCE ATa
1290 1314 1616 1647
1 (Q) 47 6 A A A C
2 (Q) 142 1 A G A C
3 A A A C
3 (R) 103 2 A A G C
3 A A A C
4 (R) 169 1 G A A C
3 A A A T
a Nucleotide position of mRNA, from initiator ATG.
proinflammatory cytokine, has been shown to decrease
PON1 expression in human HepG2 cells and PON1
activity in the plasma of mice (Van Lenten et al. 2001).
The data shown in figure 1 indicate that possessing
efficient PON1 regulatory regions does not alone guar-
antee a high PON1-activity level. Environmental fac-
tors—such as smoking (Nishio and Watanabe 1997;
James et al. 2000a; Jarvik et al. 2000) or a high-fat diet
(Shih et al. 1996; Hedrick et al. 2000)—may decrease
PON1 expression and PON1 activity and may also ex-
plain why individuals with efficient regulatory regions
have low levels of plasma-PON1 activity. Conversely,
consumption of antioxidants—such as those found in
pomegranate juice (Aviram et al. 2000), red wine
(Hayek et al. 1997), and other alcoholic beverages
(when consumed in moderation) (van der Gaag et al.
1999)—may allow an individual with inefficient PON1
regulatory regions to express moderate levels of protein.
However, individuals with inefficient regulatory regions
appear to be unable to express very high levels of PON1
(fig. 1).
Four sequence differences and variant poly(A) sig-
nal sequences were identified in the 3′ UTR of PON1
mRNA. Variant poly(A)-signal sequences are thought
to be used inefficiently, resulting in low levels of poly-
adenylated (stable) mRNA (Sheets et al. 1990; Edwalds-
Gilbert et al. 1997). Although the observed sequence
differences are not within the variant signal sequences,
they may affect the addition of the poly(A) tail or oth-
erwise alter the stability of the PON1 mRNA.
The108 regulatory-region polymorphism has a sig-
nificant effect on PON1 expression in humans. Toxi-
cological and epidemiological studies indicate that
PON1-expression levels affect the degree of protection
that an individual has against pesticide poisoning (Li et
al. 1993, 1995, 2000) and heart disease (reviewed in
Mackness et al. 1998a; Lusis 2000). Further under-
standing of PON1 regulatory-region function may re-
veal approaches for increasing the PON1 expression in
at-risk individuals. Because the wide variation in PON1-
activity level among individuals cannot be predicted
solely by genotype, future studies examining the rela-
tionship between PON1 and disease should include de-
terminations of plasma-PON1–activity levels. The de-
termination of PON1 status via the two-dimensional
substrate-assay protocol provides an accurate inference
of genotype at codon 192, as well as expression levels
for individuals (Richter and Furlong 1999; Brophy et
al. 2000).
Note added in proof.—It has recently been brought
to our attention that the previously designed primers for
genotyping the L55M polymorphism have a mismatch,
in the reverse primer, that allows it to bind, but not
completely. New primers were created that produce a
larger PCR product but still use the same digestion.
The new primers, AGAGGATTCAGTCTTTGAGGAAA
and CTGCCAGTCCTAGAAAACGTT, were used with
Taq polymerase at an annealing temperature of 50C,
for 30 cycles. After digestion, the products were analyzed
on a 2% agarose gel (Sigma). Digestion withNlaIII gen-
erated either 296-bp and 90-bp fragments, when a 55M
allele was present, or an undigested 386-bp fragment,
when a 55L allele was present.
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